Redx Pharma Plc REDX.L Stock
Redx Pharma Plc Price Chart
Redx Pharma Plc REDX.L Financial and Trading Overview
| Redx Pharma Plc stock price | 8.25 GBP |
| Previous Close | 27.5 GBP |
| Open | 27.01 GBP |
| Bid | 27 GBP x 0 |
| Ask | 28 GBP x 0 |
| Day's Range | 27.01 - 27.01 GBP |
| 52 Week Range | 26.5 - 70 GBP |
| Volume | 38 GBP |
| Avg. Volume | 15.09K GBP |
| Market Cap | 92.1M GBP |
| Beta (5Y Monthly) | -0.218773 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1 GBP |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
REDX.L Valuation Measures
| Enterprise Value | 76.28M GBP |
| Trailing P/E | N/A |
| Forward P/E | -0.03397484 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.282129 |
| Price/Book (mrq) | 600.2222 |
| Enterprise Value/Revenue | 6.031 |
| Enterprise Value/EBITDA | -2.876 |
Trading Information
Redx Pharma Plc Stock Price History
| Beta (5Y Monthly) | -0.218773 |
| 52-Week Change | -57.031% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 70 GBP |
| 52 Week Low | 26.5 GBP |
| 50-Day Moving Average | 30.96 GBP |
| 200-Day Moving Average | 47.66 GBP |
REDX.L Share Statistics
| Avg. Volume (3 month) | 15.09K GBP |
| Avg. Daily Volume (10-Days) | 6.45K GBP |
| Shares Outstanding | 334.91M |
| Float | 37.56M |
| Short Ratio | N/A |
| % Held by Insiders | 16.81% |
| % Held by Institutions | 79.93% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | September 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | September 30, 2023 |
Profitability
| Profit Margin | -229.34% |
| Operating Margin (ttm) | -212.93% |
| Gross Margin | 100.00% |
| EBITDA Margin | -209.70% |
Management Effectiveness
| Return on Assets (ttm) | -40.66% |
| Return on Equity (ttm) | -285.70% |
Income Statement
| Revenue (ttm) | 12.65M GBP |
| Revenue Per Share (ttm) | 0.04 GBP |
| Quarterly Revenue Growth (yoy) | -72.29% |
| Gross Profit (ttm) | 18.69M GBP |
| EBITDA | -26523000 GBP |
| Net Income Avi to Common (ttm) | -29008000 GBP |
| Diluted EPS (ttm) | -0.09 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 34.61M GBP |
| Total Cash Per Share (mrq) | 0.1 GBP |
| Total Debt (mrq) | 18.79M GBP |
| Total Debt/Equity (mrq) | 125.92 GBP |
| Current Ratio (mrq) | 1.524 |
| Book Value Per Share (mrq) | 0.045 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -29726000 GBP |
| Levered Free Cash Flow (ttm) | -20684000 GBP |
Profile of Redx Pharma Plc
| Country | United Kingdom |
| State | N/A |
| City | Macclesfield |
| Address | Alderley Park |
| ZIP | SK10 4TG |
| Phone | 44 16 2546 9900 |
| Website | https://www.redxpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 95 |
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops RXC008, a gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the RAS-RAF-MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.
Q&A For Redx Pharma Plc Stock
What is a current REDX.L stock price?
Redx Pharma Plc REDX.L stock price today per share is 8.25 GBP.
How to purchase Redx Pharma Plc stock?
You can buy REDX.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Redx Pharma Plc?
The stock symbol or ticker of Redx Pharma Plc is REDX.L.
Which industry does the Redx Pharma Plc company belong to?
The Redx Pharma Plc industry is Biotechnology.
How many shares does Redx Pharma Plc have in circulation?
The max supply of Redx Pharma Plc shares is 3.89M.
What is Redx Pharma Plc Price to Earnings Ratio (PE Ratio)?
Redx Pharma Plc PE Ratio is now.
What was Redx Pharma Plc earnings per share over the trailing 12 months (TTM)?
Redx Pharma Plc EPS is -0.1 GBP over the trailing 12 months.
Which sector does the Redx Pharma Plc company belong to?
The Redx Pharma Plc sector is Healthcare.
Redx Pharma Plc REDX.L included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| FTSE AIM All-Share Index FTAI | 755.91 GBP 966.76 USD |
-0.38
|
— — | 755.91 GBP 966.76 USD | 763.17 GBP 976.05 USD | — - | — — |
- {{ link.label }} {{link}}